Literature DB >> 10438726

CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade.

J M Tuscano1, A Riva, S N Toscano, T F Tedder, J H Kehrl.   

Abstract

CD22 is a B-cell-specific adhesion molecule that modulates BCR-mediated signal transduction. Ligation of human CD22 with monoclonal antibodies (MoAbs) that block the ligand binding site triggers rapid tyrosine phosphorylation of CD22 and primary B-cell proliferation. Because extracellular signal-regulated kinases (ERKs) couple upstream signaling pathways to gene activation and are activated by B-cell antigen receptor (BCR) signaling, we examined whether CD22 ligation also activated ERKs and/or modified BCR-induced ERK activation. Ligation of CD22 on either primary B cells or B-cell lines failed to significantly activate the mitogen activated protein kinase (MAPK) ERK-2, but did activate the stress-activated protein kinases (SAPKs; c-jun NH2-terminal kinases or JNKs). In contrast, BCR ligation resulted in ERK-2 activation without significant SAPK activation. Concurrent ligation of CD22 and BCR enhanced BCR-mediated ERK-2 activation without appreciably modulating CD22-induced SAPK activation. Consistent with its induction of SAPK activity, there was a marked increase in nuclear extracts of activator protein-1 (AP-1) and c-jun levels within 2 hours of exposure of primary B cells to the CD22 MoAb. Despite their differences in ERK activation, both CD22 and BCR ligation triggered several Burkitt lymphoma cell lines to undergo apoptosis, and the 2 stimuli together induced greater cell death than either signal alone. The pro-apoptotic effects were CD22-blocking MoAb-specific and dose-dependent. Examination of expression levels of Bcl-2 protoncogene family members (Bcl-2, Bcl-x(L), Mcl-1, and Bax) showed a downregulation of Bcl-x(L) and Mcl-1 after CD22 ligation. This study provides a plausible mechanism to explain how CD22 and BCR signaling can costimulate B-cell proliferation and induce apoptosis in Burkitt lymphoma cell lines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438726

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Positive and negative roles of CD72 in B cell function.

Authors:  Hsin-Jung Wu; Subbarao Bondada
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells.

Authors:  Mary K O'Reilly; Hua Tian; James C Paulson
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

3.  Dendritic cell-dependent inhibition of B cell proliferation requires CD22.

Authors:  Lorna Santos; Kevin E Draves; Mark Boton; Prabhjit K Grewal; Jamey D Marth; Edward A Clark
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

Review 4.  Educational paper. The development of new therapies for pediatric oncology.

Authors:  Terzah M Horton; Stacey L Berg
Journal:  Eur J Pediatr       Date:  2010-12-30       Impact factor: 3.183

5.  The pan-B cell marker CD22 is expressed on gastrointestinal eosinophils and negatively regulates tissue eosinophilia.

Authors:  Ting Wen; Melissa K Mingler; Carine Blanchard; Benjamin Wahl; Oliver Pabst; Marc E Rothenberg
Journal:  J Immunol       Date:  2011-12-21       Impact factor: 5.422

6.  CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.

Authors:  Fatih M Uckun; Patricia Goodman; Hong Ma; Ilker Dibirdik; Sanjive Qazi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-14       Impact factor: 11.205

Review 7.  CD22: an inhibitory enigma.

Authors:  Jennifer A Walker; Kenneth G C Smith
Journal:  Immunology       Date:  2007-12-07       Impact factor: 7.397

8.  Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts.

Authors:  Shiloh M Martin; Robert T O'Donnell; David L Kukis; Craig K Abbey; Hayes McKnight; Julie L Sutcliffe; Joseph M Tuscano
Journal:  Mol Imaging Biol       Date:  2008-10-24       Impact factor: 3.488

9.  Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.

Authors:  Robert T O'Donnell; Yunpeng Ma; Hayes C McKnight; David Pearson; Joseph M Tuscano
Journal:  Cancer Immunol Immunother       Date:  2009-05-13       Impact factor: 6.968

10.  Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).

Authors:  Robert T O'Donnell; Shiloh M Martin; Yunpeng Ma; William C Zamboni; Joseph M Tuscano
Journal:  Invest New Drugs       Date:  2009-03-24       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.